CN102099029A - 治疗眼部病症的霉酚酸钠的pH值特定溶液 - Google Patents

治疗眼部病症的霉酚酸钠的pH值特定溶液 Download PDF

Info

Publication number
CN102099029A
CN102099029A CN2009801265755A CN200980126575A CN102099029A CN 102099029 A CN102099029 A CN 102099029A CN 2009801265755 A CN2009801265755 A CN 2009801265755A CN 200980126575 A CN200980126575 A CN 200980126575A CN 102099029 A CN102099029 A CN 102099029A
Authority
CN
China
Prior art keywords
eye
nampa
solution
ocular
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801265755A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华·庄
克莱夫·伯奇
李·米泽恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspreva International Ltd
Original Assignee
Aspreva International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aspreva International Ltd filed Critical Aspreva International Ltd
Publication of CN102099029A publication Critical patent/CN102099029A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2009801265755A 2008-07-09 2009-07-09 治疗眼部病症的霉酚酸钠的pH值特定溶液 Pending CN102099029A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7941308P 2008-07-09 2008-07-09
US61/079,413 2008-07-09
PCT/IB2009/006683 WO2010004435A2 (en) 2008-07-09 2009-07-09 Formulations for treating eye disorders

Publications (1)

Publication Number Publication Date
CN102099029A true CN102099029A (zh) 2011-06-15

Family

ID=41505728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801265755A Pending CN102099029A (zh) 2008-07-09 2009-07-09 治疗眼部病症的霉酚酸钠的pH值特定溶液

Country Status (6)

Country Link
US (1) US20100010082A1 (enExample)
EP (1) EP2310008A4 (enExample)
JP (1) JP2011527339A (enExample)
CN (1) CN102099029A (enExample)
CA (1) CA2729834A1 (enExample)
WO (1) WO2010004435A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210196837A1 (en) * 2017-12-08 2021-07-01 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN113473970A (zh) * 2018-12-27 2021-10-01 瑟菲斯眼科股份有限公司 用以治疗眼表疾病的眼科药物组合物和方法
CN113519461A (zh) * 2021-07-06 2021-10-22 江西中洪博元生物技术有限公司 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用
CN114028334A (zh) * 2021-12-10 2022-02-11 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法
CN116133639A (zh) * 2019-12-20 2023-05-16 维奥梅治疗公司 用于治疗炎性疾病的制剂和方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102405286A (zh) 2008-09-22 2012-04-04 阿克赛医药公司 减小大小的自递送RNAi化合物
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
AU2010266539A1 (en) * 2009-06-30 2012-01-19 Allergan, Inc. Pharmaceutical ophthalmological liquid compositions containing propionic acid derivatives as a preservative
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
US8829053B2 (en) * 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
BR112015021334B1 (pt) * 2013-03-14 2020-04-07 Panoptica Inc formulação ocular tópica em suspenão e uso da mesma para tratamento e/ou melhora de uma doença do segmento posterior do olho
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
EP3137118A4 (en) 2014-05-01 2017-11-22 RXi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
CN107072203B (zh) 2014-09-09 2020-07-03 赫雷拉 A·索利斯 用黑色素及其类似物、前体和衍生物治疗和预防眼部疾病、障碍和病症的方法
US9789080B2 (en) * 2015-09-04 2017-10-17 Insite Vision Incorporated Ophthalmic formulations of mycophenolic acid
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20230158045A1 (en) * 2017-09-25 2023-05-25 Surface Ophthalmics, Inc. Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
EP0391909B1 (en) * 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ATE303143T1 (de) * 1993-10-01 2005-09-15 Roche Palo Alto Llc Hochdosierte oral anzuwendende suspensionen enthaltendmycophenolat mofetil
JPH0930966A (ja) * 1995-07-24 1997-02-04 Gakuzo Tamura 眼科用新規製剤
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
CN101014584A (zh) * 2004-07-20 2007-08-08 特瓦药厂私人有限公司 结晶霉酚酸钠的制备方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210196837A1 (en) * 2017-12-08 2021-07-01 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN113473970A (zh) * 2018-12-27 2021-10-01 瑟菲斯眼科股份有限公司 用以治疗眼表疾病的眼科药物组合物和方法
CN116133639A (zh) * 2019-12-20 2023-05-16 维奥梅治疗公司 用于治疗炎性疾病的制剂和方法
CN113519461A (zh) * 2021-07-06 2021-10-22 江西中洪博元生物技术有限公司 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用
CN114028334A (zh) * 2021-12-10 2022-02-11 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法

Also Published As

Publication number Publication date
WO2010004435A2 (en) 2010-01-14
CA2729834A1 (en) 2010-01-14
WO2010004435A9 (en) 2010-08-26
JP2011527339A (ja) 2011-10-27
EP2310008A2 (en) 2011-04-20
EP2310008A4 (en) 2014-03-05
US20100010082A1 (en) 2010-01-14
WO2010004435A3 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
CN102099029A (zh) 治疗眼部病症的霉酚酸钠的pH值特定溶液
AU2017380769B2 (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
US20220184057A1 (en) Combination treatment of ocular inflammatory disorders and diseases
Agrahari et al. A comprehensive insight on ocular pharmacokinetics
US6579901B2 (en) Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye
Song et al. Preparation and evaluation of sinomenine hydrochloride in situ gel for uveitis treatment
Okabe et al. Effect of benzalkonium chloride on transscleral drug delivery
US20130190278A1 (en) Compounds for the Treatment/Prevention of Ocular Inflammatory Diseases
WO2004069157A2 (en) Combinational use of long-acting and short-acting anti-histamines for ocular allergies
US20170065611A1 (en) Topical formulations and uses thereof
JP2007530573A (ja) ドライアイの治療にロテプレドノールエタボネートを使用すること
CN114126580A (zh) 用于治疗眼部过敏的眼用组合物
US20140322193A1 (en) Therapies for Disorders of the Cornea and Conjunctiva
Heitzmann et al. A review of the efficacy, safety and tolerability of Lacrycon® eye drops for the treatment of dry eye syndrome
JP4475802B2 (ja) 緑内障の局所治療用フルナリジンの使用法
Albialy et al. Safety and efficacy of intracameral injection of dexamethasone and moxifloxacin at the end of cataract surgery
CN114040783A (zh) 可用于治疗干眼症的组合物和方法
US20190247302A1 (en) Materials and methods for treating ophthalmic inflammation
US20170014487A1 (en) Method for treating ocular inflammation
US20180221417A1 (en) Treatment of dry eye using amnion released factors
WO2011107981A1 (en) A3ar agonists for the treatment of uveitis
HK40014746A (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110615